Nantahala Capital Management, LLC - 17 Dec 2025 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role: 10%+ Owner
Signature: /s/ Taki Vasilakis, Chief Compliance Officer, Nantahala Capital Management, LLC
Issuer symbol: EVOK
Transactions as of: 17 Dec 2025
Net transactions value: -$12,001,796
Form type: 4
Filing time: 19 Dec 2025, 16:15:35 UTC
Previous filing: 09 Jun 2025
Next filing: 17 Mar 2026
SEC: View on sec.gov

Reporting Owners (3)

Name	Relationship	Address	Signature	Signature date	CIK
Nantahala Capital Management, LLC	10%+ Owner	130 MAIN ST. 2ND FLOOR, NEW CANAAN	/s/ Taki Vasilakis, Chief Compliance Officer, Nantahala Capital Management, LLC	19 Dec 2025	0001472322
Harkey Wilmot B.	10%+ Owner	130 MAIN ST. 2ND FLOOR, NEW CANAAN	/s/ Wilmot B. Harkey	19 Dec 2025	0001775952
Mack Daniel	10%+ Owner	130 MAIN ST. 2ND FLOOR, NEW CANAAN	/s/ Daniel Mack	19 Dec 2025	0001775831

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVOK	Common Stock	Other	$1,629,683	-148,153	-100%	$11.00	0	17 Dec 2025	See Footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVOK	Prefunded Warrants	Other	$4,773,148	-433,962	-100%	$11.00	17 Dec 2025	Common Stock	433,962	$0.000100	See Footnote	F1, F2
transaction	EVOK	Series A Common Stock Purchase Warrants	Other	$551,159	-117,019	-100%	$4.71	17 Dec 2025	Common Stock	117,019	$8.16	See Footnote	F1, F2
transaction	EVOK	Series C Common Stock Purchase Warrants	Other	$551,159	-117,019	-100%	$4.71	17 Dec 2025	Common Stock	117,019	$8.16	See Footnote	F1, F2
transaction	EVOK	Amended Series A Common Stock Purchase Warrants	Other	$1,742,256	-158,531	-100%	$10.99	17 Dec 2025	Common Stock	158,531	$0.0100	See Footnote	F1, F2
transaction	EVOK	Amended Series C Common Stock Purchase Warrants	Other	$2,754,391	-250,627	-100%	$10.99	17 Dec 2025	Common Stock	250,627	$0.0100	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Nantahala Capital Management, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
F2	Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Evoke Pharma, Inc. ("Issuer") securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

Content

These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.

Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Evoke Pharma, Inc. ("Issuer") securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.